PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis

Drug News and Perspectives

Volumn 23, Issue 5, 2010, Pages 305-315

  Duffield, Jeremy S ^a   Lupher Jr , Mark L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Promedior Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTRAXIN; PRM 151; RECOMBINANT HUMAN SERUM AMYLOID P; SERUM AMYLOID P; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; HOMEODOMAIN PROTEIN; NERVE PROTEIN; NEURONAL PENTRAXIN; PRM-151; RECOMBINANT PROTEIN;

AMYLOIDOSIS; CELL ACTIVATION; CLINICAL TRIAL; CYTOLOGY; DRUG ACTIVITY; FIBROSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MOLECULAR BIOLOGY; MONOCYTE; NONHUMAN; REVIEW; ANIMAL; CELL DIFFERENTIATION; CELL LINEAGE; DRUG EFFECTS; PATHOLOGY;

AMYLOIDOSIS; ANIMALS; C-REACTIVE PROTEIN; CELL DIFFERENTIATION; CELL LINEAGE; FIBROSIS; HOMEODOMAIN PROTEINS; HUMANS; NERVE TISSUE PROTEINS; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT;

EID: 77953893081     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.5.1444206     Document Type: Review

References (93)

1. Pilling, D., Buckley, C.D., Salmon, M., Gomer, R.H. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003, 171(10): 5537-46.
2. Castano, A., Lin, S.L., Surowy, T. et al. Serum amyloid P inhibits fibrosis through FcgammaR-dependent monocyte/macrophage regulation in vivo. Sci Trans Med 2009, 1(5): 5ra13.
3. Haudek, S.B., Trial, J., Xia, Y., Gupta, D., Pilling, D., Entman, M.L. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci U S A 2008, 105(29): 10179-84.
4. Haudek, S.B., Xia, Y., Huebener, P. et al. Bone marrow-derived fibroblast precursors mediate Ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103(48): 18284-9.
5. Naik-Mathuria, B., Pilling, D., Crawford, J.R., Gay, A.N., Smith, C.W., Gomer, R.H., Olutoye, O.O. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 2008, 16(2): 266-73.
6. Promedior initiates phase 1 clinical trial of PRM-151, a novel compound for the treatment of fibrotic diseases and tissue remodeling [news release]; July 23, 2009. Promedior, Inc. http://www.promedior.com/072309-press.html. Accessed May 31, 2010.
7. Lupher, M.L., Jr., Gallatin, W.M. Regulation of fibrosis by the immune system. Adv Immunol 2006, 89: 245-88.
8. Friedman, S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134(6): 1655-69.
9. Lin, S.-L., Kisseleva, T., Brenner, D.A., Duffield, J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173(6): 1617-27.
10. Gomperts, B.N., Strieter, R.M. Fibrocytes in lung disease. J Leukoc Biol 2007, 82(3): 449-56.
11. Mehrad, B., Burdick, M.D., Zisman, D.A., Keane, M.P., Belperio, J.A., Strieter, R.M. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353(1): 104-8.
12. Pilling, D., Gomer, R. Regulatory pathways for fibrocyte differentiation. In: Bucala, R. (Ed.) Fibrocytes: New Insights into Tissue Repair and Systemic Fibroses: World Scientific: 2007, 37-60.
13. Quan, T.E., Cowper, S.E., Bucala, R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006, 8(2): 145-50.
14. Kim, K.K., Kugler, M.C., Wolters, P.J. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006, 103(35): 13180-5.
15. Neilson, E.G. Mechanisms of disease: Fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2006, 2(2): 101-8.
16. Lin, S.L., Castano, A.P., Nowlin, B.T., Lupher, M.L., Jr., Duffield, J.S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009, 183(10): 6733-43.
17. Humphreys, B.D., Lin, S.L., Kobayashi, A. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176(1): 85-97.
18. Duffield, J.S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 2003, 104(1): 27-38.
19. Gordon, S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1): 23-35.
20. Mantovani, A., Sica, A., Locati, M. Macrophage polarization comes of age. Immunity 2005, 23(4): 344-6.
21. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25(12): 677-86.
22. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23(11): 549-55.
23. Duffield, J.S., Forbes, S.J., Constandinou, C.M. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115(1): 56-65.
24. Duffield, J.S., Tipping, P.G., Kipari, T. et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167(5): 1207-19.
25. Fallowfield, J.A., Mizuno, M., Kendall, T.J., Constandinou, C.M., Benyon, R.C., Duffield, J.S., Iredale, J.P. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007, 178(8): 5288-95.
26. Mosser, D.M., Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8(12): 958-69.
27. Garlanda, C., Bottazzi, B., Bastone, A., Mantovani, A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23: 337-66.
28. Mantovani, A., Garlanda, C., Doni, A., Bottazzi, B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008, 28(1): 1-13.
29. Gewurz, H., Zhang, X.H., Lint, T.F. Structure and function of the pentraxins. Curr Opin Immunol 1995, 7(1): 54-64.
30. Steel, D.M., Whitehead, A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994, 15(2): 81-8.
31. Pepys, M.B., Booth, D.R., Hutchinson, W.L., Gallimore, J.R., Collins, P.M., Hohenester, E. Amyloid P component. A critical review. Amyloid: Int J Exp Clin Invest 1997, 4: 274-95.
32. Lu, J., Marnell, L.L., Marjon, K.D., Mold, C., Du Clos, T.W., Sun, P.D. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008, 456(7224): 989-92.
33. Tennent, G.A., Dziadzio, M., Triantafillidou, E., Davies, P., Gallimore, J.R., Denton, C.P., Pepys, M.B. Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum 2007, 56(6): 2013-7.
34. Bijl, M., Bootsma, H., van der Geld, Y., Limburg, P.C., Kallenberg, C.G.M., van Rijswijk, M.H. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004, 63(7): 831-5.
35. Jenny, N.S., Arnold, A.M., Kuller, L.H., Tracy, R.P., Psaty, B.M. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2007, 27(2): 352-8.
36. Nelson, S.R., Tennent, G.A., Sethi, D., Gower, P.E., Ballardie, F.W., Amatayakul-Chantler, S., Pepys, M.B. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991, 200(2-3): 191-9.
37. Mortensen, R.F., Beisel, K., Zeleznik, N.J., Le, P.T. Acute-phase reactants of mice. II. Strain dependence of serum amyloid P-component (SAP) levels and response to inflammation. J Immunol 1983, 130(2): 885-9.
38. Whitehead, A.S., Rits, M. Characterization of the gene encoding mouse serum amyloid P component. Comparison with genes encoding other pentraxins. Biochem J 1989, 263(1): 25-31.
39. Steel, D.M., Whitehead, A.S. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PRF/5. Biochem J 1991, 277 (Pt 2): 477-82.
40. Pilling, D., Roife, D., Wang, M., Ronkainen, S.D., Crawford, J.R., Travis, E.L., Gomer, R.H. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007, 179(6): 4035-44.
41. Pilling, D., Tucker, N.M., Gomer, R.H. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006, 79(6): 1242-51.
42. Gershov, D., Kim, S., Brot, N., Elkon, K.B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192(9): 1353-64.
43. Fadok, V.A., Bratton, D.L., Konowal, A., Freed, P.W., Westcott, J.Y., Henson, P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TCF-beta, PGE2, and PAF. J Clin Invest 1998, 101(4): 890-8.
44. Bijl, M., Horst, G., Bijzet, J., Bootsma, H., Limburg, P.C., Kallenberg, C.G. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum 2003, 48(1): 248-54.
45. Ciurana, C.L., Hack, C.E. Competitive binding of pentraxins and IgM to newly exposed epitopes on late apoptotic cells. Cell Immunol 2006, 239(1): 14-21.
46. Familian, A., Zwart, B., Huisman, H.G. et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 2001, 167(2): 647-54.
47. Mold, C., Baca, R., Du Clos, T.W. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 2002, 19(3): 147-54.
48. Canbay, A., Friedman, S., Gores, G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39(2): 273-8.
49. Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., Gores, G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83(5): 655-63.
50. Lin, S.L., Kisseleva, T., Brenner, D.A., Duffield, J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173(6): 1617-27.
51. Bharadwaj, D., Mold, C., Markham, E., Du Clos, T.W. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol 2001, 166(11): 6735-41.
52. Mold, C., Gresham, H.D., Du Clos, T.W. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol 2001, 166(2): 1200-5.
53. Murray, L.A., Rosada, R., Moreira, A.P. et al. Serum amyloid P therapeuticallly attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5(3): e9683.
54. Jakubzick, C., Choi, E.S., Joshi, B.H., Keane, M.P., Kunkel, S.L., Puri, R.K., Hogaboam, C.M. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol 2003, 171(5): 2684-93.
55. Botto, M., Hawkins, P.N., Bickerstaff, M.C. et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997, 3(8): 855-9.
56. Togashi, S., Lim, S.K., Kawano, H. et al. Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 1997, 77(5): 525-31.
57. Gillmore, J.D., Hutchinson, W.L., Herbert, J. et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Immunology 2004, 112(2): 255-64.
58. Bickerstaff, M.C., Botto, M., Hutchinson, W.L. et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999, 5(6): 694-7.
59. Kolstoe, S., Wood, S. Perspectives for drug intervention in amyloid diseases. Curr Drug Targets 2004, 5(2): 151-8.
60. Serpell, L.C. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000, 1502(1): 16-30.
61. Bogers, W.M., van Rooijen, N., Janssen, D.J., van Es, L.A., Daha, M.R. Complement enhances the elimination of soluble aggregates of IgG by rat liver endothelial cells in vivo. Eur J Immunol 1993, 23(2): 433-8.
62. Gebska, M.A., Titley, I., Paterson, H.F. et al. High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood 2002, 99(6): 2221-7.
63. Ashton, A.W., Boehm, M.K., Gallimore, J.R., Pepys, M.B., Perkins, S.J. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol 1997, 272(3): 408-22.
64. Cathcart, E.S., Wollheim, F.A., Cohen, A.S. Plasma protein constituents of amyloid fibrils. J Immunol 1967, 99(2): 376-85.
65. Hawkins, P.N. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002, 11(6): 649-55.
66. Tennent, G.A., Lovat, L.B., Pepys, M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995, 92(10): 4299-303.
67. Janciauskiene, S., Garcia de Frutos, P., Carlemalm, E., Dahlback, B., Eriksson, S. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem 1995, 270(44): 26041-4.
68. Inoue, S., Kawano, H., Ishihara, T., Maeda, S., Ohno, S. Formation of experimental murine AA amyloid fibrils in SAP-deficient mice: high resolution ultrastructural study. Amyloid 2005, 12(3): 157-63.
69. Murakami, T., Yi, S., Maeda, S. et al. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Am J Pathol 1992, 141(2): 451-6.
70. Snel, F.W., Niewold, T.A., Baltz, M.L., Hol, P.R., Van Ederen, A.M., Pepys, M.B., Gruys, E. Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition. Clin Exp Immunol 1989, 76(2): 296-300.
71. Tashiro, F., Yi, S., Wakasugi, S., Maeda, S., Shimada, K., Yamamura, K. Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene. Gerontology 1991, 37 Suppl 1: 56-62.
72. Usui, I., Kawano, H., Ito, S., Hamada, Y., Ishihara, T., Maeda, S. Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits. Amyloid 2001, 8(2): 101-4.
73. Gillmore, J.D., Tennent, G.A., Hutchinson, W.L. et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010, 148(5): 760-7
74. Hamazaki, H. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. J Biol Chem 1995, 270(18): 10392-4.
75. Urbanyi, Z. The role of serum amyloid P (SAP) component in Alzheimer's disease. Neurobiology (Bp) 1996, 4(3): 283-4.
76. Duong, T., Acton, P.J., Johnson, R.A. The in vitro neuronal toxicity of pentraxins associated with Alzheimer's disease brain lesions. Brain Res 1998, 813(2): 303-12.
77. Urbanyi, Z., Sass, M., Laszy, J., Takacs, V., Gyertyan, I., Pazmany, T. Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res 2007, 1145: 221-6.
78. Lovat, L.B., O'Brien, A.A., Armstrong, S.F. et al. Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. Alzheimer Dis Assoc Disord 1998, 12(3): 208-10.
79. Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000, 887(1): 80-9.
80. Verwey, N.A., Schuitemaker, A., van der Flier, W.M. et al. Serum amyloid P component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2008, 26(6): 522-7.
81. Kimura, M., Asada, T., Uno, M. et al. Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 1999, 273(2): 137-9.
82. Mulder, C., Schoonenboom, S.N., Wahlund, L.O. et al. CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J Neural Transm 2002, 109(12): 1491-8.
83. Hawkins, P.N., Rossor, M.N., Gallimore, J.R., Miller, B., Moore, E.G., Pepys, M.B. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 1994, 201(2): 722-6.
84. Baltz, M.L., Dyck, R.F., Pepys, M.B. Studies of the in vivo synthesis and cotabolism of serum amyloid P component (SAP) in the mouse. Clin Exp Immunol 1985, 59(1): 235-42.
85. de Beer, F.C., Baltz, M.L., Munn, E.A. et al. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 1982, 45(1): 55-70.
86. Nakada, H., Matsumoto, S., Tashiro, Y. Biosynthesis and secretion of amyloid P component in rat liver. J Biochem (Tokyo) 1986, 99(3): 877-84.
87. Hawkins, P.N., Tennent, G.A., Woo, P., Pepys, M.B. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 1991, 84(2): 308-16.
88. Hawkins, P.N., Wootton, R., Pepys, M.B. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990, 86(6): 1862-9.
89. Promedior, Inc. Web site. http://www.promedior.com. Accessed May 31, 2010.
90. European Commission grants Promedior's PRM-151 Orphan Drug Designation for the prevention of scarring post glaucoma filtration surgery [news release]; October 29, 2009. Promedior, Inc. http://www.promedior.com/091029-press.html. Accessed May 31, 2010.
91. Moreland, J.L., Gramada, A., Buzko, O.V., Zhang, Q., Bourne, P.E. The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics 2005, 6: 21.
92. Emsley, J., White, H.E., O'Hara, B.P. et al. Structure of pentameric human serum amyloid P component. Nature 1994, 367(6461): 338-45.
93. Bang, R., Marnell, L., Mold, C., Stein, M.P., Clos, K.T., Chivington-Buck, C., Clos, T.W. Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis. J Biol Chem 2005, 280(26): 25095-102.